ORION CORPORATION                 PRESS RELEASE                 10 SEPTEMBER 2019        

Orion recalls Melatoniini Orion 1 mg Spray 20 ml oral spray from consumers


Orion is recalling the Melatoniini Orion 1 mg Spray 20 ml product batch number 1901020001 from consumers due to an issue with shelf-life.

Consumers are requested to return both opened and unopened Melatoniini Orion 1 mg Spray 20 ml oral spray products to the nearest pharmacy by 31 October 2019. Consumers will be fully reimbursed the products by the pharmacies.

The recall does not concern other Melatoniini Orion products.

Melatoniini Orion 1 mg Spray is a nutritional supplement.


Further information:

Product information and customer service: tel. 010 439 8250

Contact with the media: Terhi Ormio, Vice President, Communications, tel. 050 966 4646



Orion Corporation
Orionintie 1A, FI-02200 Espoo, Finland

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2018 amounted to EUR 977 million and the company had about 3,200 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.